Drug intelligence / Profile preview

miR-20a inhibitor

Development stage
Preclinical
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intrathecal, Intravenous, Subcutaneous
01

Overview

miR-20a inhibitors are a class of RNA-based molecules, typically antisense oligonucleotides or antagomirs, designed to selectively bind and neutralize microRNA-20a (miR-20a). miR-20a is a member of the miR-17-92 cluster, an 'oncomir' cluster that is frequently overexpressed in various malignancies, including multiple myeloma, lymphomas, and solid tumors. By sequestering miR-20a, these inhibitors prevent it from downregulating its target tumor-suppressor mRNAs, thereby promoting apoptosis and inhibiting the proliferation of cancer cells. In research settings, miR-20a inhibitors have been shown to sensitize multiple myeloma cells to proteasome inhibitors like bortezomib. While primarily used as laboratory tools to investigate microRNA function, they represent a potential therapeutic strategy for diseases characterized by miR-20a dysregulation.

Other names
anti-miR-20aanti-miR20aanti-miR 20amiR-20a antagomirmiR20a antagomirmiR 20a antagomirmicroRNA-20a inhibitormicroRNA20a inhibitormicroRNA 20a inhibitor
02

Targets

miR-20a (microRNA-20a)

Beyond the preview

Go deeper on miR-20a inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-20a inhibitor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call